GlassScriptPhysician profile
John Peter Birgiolas
NPI 1639309388
$2,670.99
in general payments reported to CMS, 2019-2025
25 companies · $406 in 2025
The $406 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $578 · 2020: $237 · 2021: $198 · 2022: $316 · 2023: $536 · 2024: $401 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,342.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $547.12 | 2019-2024 | Senza |
| Abbott Laboratories | $326.28 | 2019-2025 | Proclaim |
| Boston Scientific Corporation | $315.22 | 2019-2022 | |
| Abbvie INC. | $160.05 | 2023-2025 | Ubrelvy, Qulipta |
| Teva Pharmaceuticals USA, INC. | $142.70 | 2019-2024 | Ajovy |
| Globus Medical, INC. | $136.67 | 2025 | Senza |
| Saluda Medical Americas, INC. | $124.93 | 2025 | Evoke |
| Pfizer INC. | $122.63 | 2019-2024 | |
| Collegium Pharmaceutical, INC. | $113.43 | 2023-2024 | Belbuca, Xtampza |
| Assertio Therapeutics, INC. | $79.57 | 2019 | |
| Novartis Pharmaceuticals Corporation | $65.65 | 2019 | |
| Allergan, INC. | $65.56 | 2019-2020 | |
| Medtronic, INC. | $63.58 | 2022-2024 | Intellis Adaptivestim |
| Vertiflex, INC. | $57.97 | 2019 | |
| Painteq LLC | $57.24 | 2024 | Painteq |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spinal Simplicity, LLC | $46.16 | 2025 | Ha Minuteman G3-R |
| Lilly USA, LLC | $42.62 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $39.49 | 2019-2020 | |
| Relievant Medsystems, INC. | $36.78 | 2020 | |
| Hydrocision, INC. | $35.44 | 2020 | |
| Vertical Pharmaceuticals, LLC | $25.53 | 2019 | |
| Amgen INC. | $21.51 | 2019 | |
| Medtronic USA, INC. | $16.76 | 2019 | |
| Spr Therapeutics, INC | $14.63 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Birgiolas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.